4 FDA decisions to look for in July

The Food and Drug Administration has approved 22 new drugs so far in 2017, with a handful of regulatory decisions scheduled for this month, according to Zacks Investment Research.

Here are four companies awaiting regulatory decisions in July, as listed by Zacks.

  1. Puma Biotechnology seeks FDA approval for neratinib — a follow-up treatment for a form of early stage breast cancer. The drug company expects a response from the FDA by the end of the month.

  1. Ocular Therapeutix's drug Dextenza is a treatment for eye pain following ophthalmic surgery. The company expects a response from the FDA July 19.

  1. Eagle Pharmaceuticals expects to hear from the FDA on July 23 regarding the review of its external heat stroke treatment Ryanodex.

  1. Amgen and UCB will learn if their osteoporosis drug Evenity earns FDA approval July 19.

More articles on supply chain:

6 drugmakers in the headlines
10 most-read supply chain stories in June
Teens have limited access to emergency contraception: 4 study findings

Copyright © 2023 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


Featured Whitepapers

Featured Webinars